Stockscreener 앱 받기
4.185
3.88%
-0.165
Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스
What analysts say about Perspective Therapeutics Inc. stockUnmatched market performance - Autocar Professional
Perspective Therapeutics Inc. Stock Analysis and ForecastHigh-octane investment gains - Autocar Professional
Is Perspective Therapeutics Inc. a good long term investmentTriple-digit profit margins - Autocar Professional
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - MarketScreener
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga
What drives Perspective Therapeutics Inc. stock priceFastest return on investment - Autocar Professional
Why Perspective Therapeutics Inc. stock attracts strong analyst attentionFree Best Performing Stock Alerts - Newser
How Perspective Therapeutics Inc. stock performs during market volatilityIntraday Trade Ideas - Newser
What makes Perspective Therapeutics Inc. stock price move sharplyHigh Return Setup Scanner - Newser
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2025 Financial Results - The Manila Times
Cancer Treatment Pioneer Perspective Therapeutics Announces Q2 2025 Earnings Date: Key Updates Coming - Stock Titan
Top Reasons to Buy SBT(sbtcoin)Free Stock Market Practical Discussion Forums - newser.com
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Perspective Therapeutics Inc (CATX Stock: A Sea of Opportunity - investchronicle.com
Perspective Therapeutics Updates Strategic Focus on Radiopharmaceuticals - TipRanks
Perspective Therapeutics, Inc.(NYSEAM: CATX) dropped from Russell 3000 Growth Index - MarketScreener
Analysts Offer Insights on Healthcare Companies: BeiGene (ONC), Vertex Pharmaceuticals (VRTX) and Edgewise Therapeutics (EWTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Perspective Therapeutics (CATX) and Codexis (CDXS) - The Globe and Mail
Perspective Therapeutics (CATX) Maintains 'Outperform' Rating by Wedbush | CATX Stock News - GuruFocus
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial - Yahoo Finance
Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going - Finansavisen
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Average Rating of “Buy” from Analysts - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Bank of America Corp DE - Defense World
Analyzing Ratios: Perspective Therapeutics Inc (CATX)’s Financial Story Unveiled - DWinneX
New Research Reveals Top 6 Radioligand Therapy Companies Transforming Cancer Treatment in $13B Market - Stock Titan
The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic - insights.citeline.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Warren Buffett Says Buy This Index Fund, and Here's How It Could Turn $500 Per Month Into $1 Million - The Globe and Mail
Cantor Fitzgerald Forecasts CATX FY2026 Earnings - Defense World
0.09%
0.32%
자본화:
|
볼륨(24시간):